2021年CRI China greenlights self-developed vaccine for public use（在线收听）

China greenlights self-developed vaccine for public use

China has begun its mass COVID-19 vaccination program after the country approved one homegrown vaccine. Sinopharm says interim results from the final stage clinical trials show its vaccine has an efficacy rate of 79.34 percent. Different from some Western counterparts, the Chinese vaccine is inactivated and can be produced relatively easier and quickly.